Clinical Trial Update: Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Dornase Alfa for ARDS in patients with SARS-CoV-2 completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Dornase alfa (dornase alfa)

Snippet

Sponsor: University of Missouri-Columbia | Conditions: SARS-CoV 2, ARDS | Phase 3 | Status: COMPLETED | Results posted: 2021-04-14